PCSK9 and atherosclerosis: Therefore, it may not be sufficient to select hs-CRP as the only biomarker reflecting the intensity of the inflammatory response, and PCSK9 inhibitors are useful to inhibit the local inflammatory response in ASCVD patients (14, 96).